Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Department of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
J Thromb Haemost. 2023 Mar;21(3):691-699. doi: 10.1016/j.jtha.2022.11.032. Epub 2022 Dec 22.
Disseminated intravascular coagulation (DIC) is not a disease criterion but a pathomechanistic process that accompanies various underlying diseases. According to the International Society on Thrombosis and Haemostasis definition, endothelial injury is an essential component in addition to systemic coagulation activation. Despite this definition, current diagnostic criteria for DIC do not include biomarkers for vascular endothelial injury. Endothelial cells are critical for hemostatic regulation because they produce various antithrombotic substances and express anticoagulant factors at the same time as facilitating coagulation, inflammatory reactions, platelet aggregation, and fibrinolysis with acute injury. Endothelial cells also exhibit various receptors, adhesion molecules, and the critical role of glycocalyx that regulates cellular interactions in thromboinflammation. For clinicians, biomarkers suitable for assessing endothelial injury are not readily available. Although we still do not have ideal biomarkers, antithrombin activity and von Willebrand factor can be candidates for the endothelium-related markers because those reflect the severity and are available in most clinical settings. Further, the dysfunction of endothelial cell in DIC arising from various underlying diseases is likely highly variable. For example, the involvement of endothelial dysfunction is significant in sepsis-induced coagulopathy, while moderate in trauma-induced coagulopathy, and variable in hematologic malignancy-associated coagulopathy. Because of the complexity of disease status associated with DIC, further research searching clinically available endothelium-related biomarkers is expected to establish individualized diagnostic criteria and potential therapeutic approaches.
弥散性血管内凝血(DIC)不是一种疾病标准,而是一种伴随各种基础疾病的病理生理过程。根据国际血栓与止血学会的定义,内皮损伤是除系统性凝血激活之外的一个必要组成部分。尽管有了这个定义,DIC 的现行诊断标准仍未包括血管内皮损伤的生物标志物。内皮细胞对于止血调节至关重要,因为它们在促进凝血、炎症反应、血小板聚集和纤维蛋白溶解的同时产生各种抗血栓物质和表达抗凝因子。内皮细胞还具有各种受体、粘附分子和糖萼的关键作用,糖萼调节血栓炎症中的细胞相互作用。对于临床医生来说,评估内皮损伤的合适生物标志物并不容易获得。尽管我们仍然没有理想的生物标志物,但抗凝血酶活性和血管性血友病因子可以作为与内皮相关的标志物候选物,因为它们反映了严重程度,并且在大多数临床环境中都可用。此外,各种基础疾病引起的 DIC 中内皮细胞功能障碍可能高度可变。例如,内皮功能障碍在脓毒症引起的凝血障碍中很重要,而在创伤引起的凝血障碍中则中等,在血液恶性肿瘤相关的凝血障碍中则不同。由于与 DIC 相关的疾病状态的复杂性,预计将进行进一步的研究,以寻找临床上可用的内皮相关生物标志物,从而建立个体化的诊断标准和潜在的治疗方法。